Study links weight-loss drugs to 21% lower fracture risk

UCLA Health researchers reported on August 4 that GLP-1 receptor agonists were associated with a lower risk of fragility fractures in adults with type 2 diabetes, adding bone health data to a drug class better known for lowering blood sugar and body weight. The finding comes from a comparative effectiveness study of U.S. electronic health records that tracked patients for up to three years. Euronews reported the study on Thursday, August 6, after the paper appeared in JAMA Network Open. The authors said the results challenge concerns that weight loss tied to these medicines would necessarily raise fracture risk. ### Which drugs did the study examine? JAMA Network Open said the analysis compared people who started a GLP-1 receptor agonist with people who started a dipeptidyl peptidase-4 inhibitor, or DPP-4 inhibitor, another common treatment for type 2 diabetes. The study used data from the TriNetX Research Network, a multicenter U.S. electronic health record database, covering the period from January 1, 2015, to December 31, 2022. (euronews.com) UCLA Health said the study focused on adults ages 50 to 90 with type 2 diabetes. After matching, the final cohorts included 133,606 patients, split evenly between 66,803 GLP-1 users and 66,803 DPP-4 users. ### What does the 21% figure actually mean? The study reported a hazard ratio of 0.79, which corresponds to a 21% lower relative risk of fragility fracture over three years for patients who initiated a GLP-1 drug rather than a DPP-4 inhibitor. (pubmed.ncbi.nlm.nih.gov) PubMed’s abstract also reported an absolute risk reduction of 0.79 percentage points and a number needed to treat of 126. UCLA Health said the biggest reductions were seen in fractures of the hip, femur and spine. The primary outcome was incident fragility fracture, defined in the paper as fractures after low-energy trauma such as a fall from standing height. ### Did the study say weight loss explained the lower fracture risk? The authors reported that the association was independent of changes in body mass index and hemoglobin A1c, a measure of blood sugar control. (pubmed.ncbi.nlm.nih.gov) That matters because one question around GLP-1 drugs has been whether rapid weight loss could weaken bone and increase fractures. The study’s mediation analysis did not find that changes in BMI or A1c explained the lower fracture risk. Medical Xpress, citing the UCLA release, said a separate analysis found the reduced risk was associated with participants who had type 2 diabetes, compared with a matched cohort without diabetes. ### How strong is this evidence? The paper described the work as a retrospective target trial emulation, not a randomized clinical trial. (pubmed.ncbi.nlm.nih.gov) That means the researchers used observational health-record data to mimic the structure of a trial, then matched patients to reduce differences between the groups. The authors said prospective studies are needed to establish causality. (medicalxpress.com) AJMC, summarizing the paper, also noted the researchers’ warning that residual confounding and outcome misclassification remain possible in observational work. ### Why has bone health been a question for GLP-1 drugs? Earlier research had raised concern that rapid weight reduction might contribute to bone thinning and fracture risk, particularly in older adults already at higher baseline risk. (pubmed.ncbi.nlm.nih.gov) ScienceDaily, describing related research presented at ENDO 2026, said that debate helped drive recent work comparing GLP-1 medicines with other obesity and diabetes therapies. On August 6, the new JAMA Network Open paper stood out because it examined a larger diabetes cohort and compared GLP-1 users with patients starting another diabetes drug class rather than with untreated patients. The article remains available through JAMA Network Open and PubMed, where the abstract lists the study design, cohort size and three-year fracture results. (pubmed.ncbi.nlm.nih.gov) (sciencedaily.com)